Kymera hands the helm to Novartis vet — and founding CSO — Nello Mainolfi
Kymera Therapeutics is turning to a co-founder to run the company.
The protein degradation specialist with a deep-pocket syndicate behind them has opted to give the helm officially to Nello Mainolfi. The new CEO is a veteran of the Novartis Institutes for Biomedical Research. He joined Atlas Venture in their entrepreneur-in-residence program and helped launch Kymera as the CSO three years ago with Atlas’ Bruce Booth.
The boast at Kymera is that they’re angling to create a new class of protein degraders, a popular field where there’s been a variety of startups. One of its chief advocates is NIBR head Jay Bradner, who launched C4 just ahead of joining Novartis, where he’s also been doing new work in the field.
Kymera still has a very long way to go. Its lead program targeting IRAK4 is in preclinical development, and earlier efforts are crowding in behind it. A $65 million round last November brought in an international set of backers, which followed a $30 million launch round.
Mainolfi is replacing founding CEO Laurent Audoly, who left last August in pursuit of new opportunities. The new CEO got his PhD at Imperial College London.